Checkpoint Inhibitor Skin Toxicity in Urothelial Cancer: Managing Erythema Multiforme During Pembrolizumab Therapy

Checkpoint inhibitor skin toxicity surfaces in urothelial cancer care

A new case report describes erythema multiforme emerging during pembrolizumab therapy for recurrent urothelial carcinoma, underscoring how rare but consequential cutaneous immune‑related events can complicate otherwise effective cancer regimens. The clinical picture aligns with a broader trend: as indications for programmed cell death 1 (PD‑1) inhibitors expand across bladder cancer pathways, dermatologic surveillance is becoming part of routine oncology operations and a defined element of oncology quality‑assurance frameworks.

What erythema multiforme is – and how it intersects with immunotherapy

• Definition: Erythema multiforme (EM) is an acute, immune‑mediated skin eruption characterized by “targetoid” lesions, classically triggered by infections or medications; it sits on a spectrum distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).
• Immune‑checkpoint link: EM has been documented as a rare toxicity during PD‑1 blockade, including pembrolizumab. One peer‑reviewed report notes: “EM is a rare side effect of pembrolizumab, occurring in only 0.1% of patients.”
• Clinical urgency: A published summary emphasizes, “Prompt recognition and appropriate management of EM are crucial.”

In practice, differentiating EM from life‑threatening reactions such as SJS/TEN is essential for treatment decisions and care coordination. That distinction influences not only bedside choices on drug interruption or discontinuation but also how cases are graded and reported into national pharmacovigilance systems.

Where this fits in the growing urothelial cancer treatment landscape

Use of pembrolizumab in urothelial carcinoma has widened, including in first‑line combinations with the antibody-drug conjugate enfortumab vedotin for locally advanced or metastatic disease. That shift increases the absolute number of patients exposed to immunotherapy and, by extension, the volume of immune‑related adverse events health systems must triage. For hospital leaders, this is translating into new expectations around embedded dermatology support, standardized toxicity pathways, and budget lines for specialist staffing as combination regimens move from tertiary centers into broader regional networks.

Signals from research and regulators on skin adverse events

• Frequency patterns under PD‑1 therapy:
  • Maculopapular rash and pruritus are among the most common dermatologic events under anti‑PD‑1 monotherapy (often in the mid‑teens percentage range across series).
  • EM is uncommon and typically reported in case reports or small series.
• Regulatory context and governance:
  • Enfortumab vedotin, frequently paired with pembrolizumab in bladder cancer pathways, carries a boxed warning for severe cutaneous reactions, and its combination label highlights higher rates of skin events. Those warnings, issued under the U.S. Food and Drug Administration’s authority, effectively set the minimum monitoring standard that accredited cancer centers are expected to operationalize.
  • Severe cutaneous reactions, including SJS/TEN, are recognized risks within PD‑1/PD‑L1 class labeling and safety communications, reinforcing that these toxicities are not isolated anomalies but class‑wide signals that must be built into institutional risk‑management plans.

Timelines and care pathways that health systems can standardize

• Observed onset windows
  • Common rashes and pruritus: median onset often around 5-7 weeks in cohort studies, with wide variability.
  • EM: described after early cycles in published reports, but timing is inconsistent across cases.
• Operational checkpoints inside cancer programs
  • Early dermatology involvement in oncology clinics improves classification and grading (CTCAE‑based) and helps avoid unnecessary treatment interruptions. For administrators, embedding this into multidisciplinary clinics is becoming a marker of program maturity.
  • Institutional escalation algorithms should flag red‑flag features (mucosal involvement, widespread skin pain, blistering) for urgent, multidisciplinary review. Many centers now hard‑wire these criteria into order sets and triage dashboards to satisfy internal governance and external accreditation requirements.

Pharmacovigilance, reporting and policy feedback loops

• With broader first‑line use of enfortumab vedotin plus pembrolizumab in urothelial cancer, the denominator of exposed patients is rising, and so is the importance of capturing rare toxicities such as EM through routine safety surveillance. Timely reporting into systems such as the FDA’s MedWatch program allows regulators to adjust product labeling, issue safety communications, and, where necessary, convene advisory committees.
• Boxed warnings and label updates on severe skin reactions are designed to harmonize monitoring and escalation standards across sites of care. In practical terms, they drive updates to institutional protocols, payer prior‑authorization criteria, and medico‑legal expectations around documentation and patient counseling.

Equity and access implications

• Patients treated outside major centers may have limited same‑day access to dermatology, prolonging diagnostic uncertainty and increasing the risk of unnecessary treatment delays. For health‑system leaders, this raises questions about how novel immunotherapy combinations are rolled out across urban and rural networks.
• Integration of teledermatology and standardized photo documentation can support timely grading and decision‑making across community settings, reducing disparities in adverse‑event management. Some regional systems are now piloting hub‑and‑spoke models in which tertiary‑center dermatologists review complex cases remotely before decisions on holding or resuming immunotherapy.

Expert consensus highlights collaborative decision‑making

Published authors stress shared decision‑making when cutaneous toxicities surface during PD‑1 therapy: “Decisions regarding the continuation of PBZ therapy should be made collaboratively by dermatologists and oncologists.” That framing reflects a maturing consensus to weigh cancer control alongside safety when rare events like EM arise, with tumor boards, toxicity committees, and, increasingly, patient‑reported outcome data feeding into whether to continue, hold, or permanently discontinue treatment.

Documentation and resources

• Case literature describing EM with PD‑1 blockade, including a peer‑reviewed case report and literature review, continues to expand the evidence base clinicians use to distinguish EM from more severe reactions and to refine local management algorithms.
• Therapeutic expansion in urothelial cancer, such as the recent approval of enfortumab vedotin plus pembrolizumab, reinforces the need for system‑level readiness to manage dermatologic immune‑related adverse events alongside oncologic benefit. For policymakers and payers, the signal is clear: reimbursement, quality metrics, and workforce planning will increasingly need to account for the hidden infrastructure required to keep these powerful regimens both effective and safe.